© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Jeffrey Hertzberg, MD, MS
Articles
Probiotics: What Role, if Any, in the Management of IBS? IBD?
March 09, 2013
The mechanisms and effectiveness of probiotics in treatment of irritable bowel syndrome and inflammatory bowel disease are emerging.
Study Sheds Light on Wheat Sensitivity as an Emerging Clinical Entity
February 11, 2013
Results suggest that wheat sensitivity is a true clinical entity worthy of further study, and that it is a heterogeneous condition with at least 2 distinct subtypes. How this will translate into clinical practice will be an evolving research area, but clinicians should not expect gluten avoidance to disappear as yet another food fad.
Some Reassurance About Proton Pump Inhibitors and Risk of Osteoporotic Fractures
February 11, 2013
Despite limitations, this study lends some reassurance that risk of osteoporosis is not likely to overshadow the benefit of proton pump inhibitors in preventing recurrent peptic ulcer, esophageal reflux symptoms, and esophageal cancer risk.
Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection
February 07, 2013
This study ought to put concerns about handling and administration of donor feces to rest: the cure rate in this study of fecal microbiota transplant for recurrent C difficile approached 95%.
New Inflammatory Bowel Disease Therapies in Development
December 19, 2012
New drugs are needed because a significant fraction of patients reach the end of the line with existing therapies.
Inflammatory Bowel Disease Treatment Monitoring Strategies
December 19, 2012
All patients with IBD should receive aggressive ongoing assessment of their inflammatory state and its response to immunomodulators, anti-TNF drugs, and other agents.
Inflammatory Bowel Disease Treatment: Advance to Anti-TNFs?
December 18, 2012
A purely dichotomous understanding of whether to start treatment for patients who have IBD with anti-TNF agents is becoming an outdated view.
Handling Inflammatory Bowel Disease Adverse Events Resulting From Immunomodulators and Biologics
December 17, 2012
Even the most experienced and skilled gastroenterologists in the country are struggling to make science-based decisions in this area.
Ulcerative Colitis Therapy: Maximizing the Use of 5-ASA Agents
December 17, 2012
These agents remain the mainstay of therapy for the majority of patients with the disease.
Inflammatory Bowel Disease and Ulcerative Colitis: A Difficult Differential
December 17, 2012
A straightforward discussion drove toward attendees toward the more current understanding of the clinical and genetic overlap between the 2 major forms of IBD.